Drugs / Anti-PD1 armored CD19 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07368270 | Jan 2026 → Jan 2027 expected | diffuse large B-cell lymphoma | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-PD1 armored CD19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07368270 ↗ |
| Modality | Cell therapy | “CAR-T cells” NCT07368270 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT07368270 ↗ |
| Target | CD19 | “Anti-PD1 armored CD19 CAR-T cells” NCT07368270 ↗ |